Home
/

What is a Free T4 Index Blood Test?

REVIEWED BY
Bill Maish, MD
Clinical Content Consultant
Published
May 30, 2026
Last updated
May 30, 2026
Quick answer:

The Free T4 Index (FT4I or T7) is a calculated estimate of unbound thyroxine that corrects total T4 for shifts in binding proteins like TBG, clarifying true hormone availability to tissues. Low FT4I is associated with fatigue, cold intolerance, and weight gain; high FT4I with restlessness, heat intolerance, and tachycardia. It is most useful during pregnancy, estrogen therapy, or liver/kidney disease and is read alongside TSH.

Read more →
Table of contents

The FT4 Index, corrected for binding-protein swings

Free T4 Index (FT4I, also called T7) is a calculated estimate of the amount of free thyroxine in your bloodstream. Thyroxine (T4) is a hormone made by the thyroid gland and released into blood mostly attached to carrier proteins (thyroxine‑binding globulin, transthyretin, albumin). Only a small fraction is unbound (“free”) and able to act on tissues. The FT4I combines information about total circulating T4 with the blood’s binding capacity to approximate that free fraction.

The free portion of T4 is the biologically available hormone that enters cells, is converted as needed to triiodothyronine (T3), and turns on genes that set metabolic pace—energy use, heat production, oxygen consumption, and the performance of the heart, brain, muscles, and other organs. Because it accounts for variations in binding proteins, the Free T4 Index is designed to reflect the thyroid hormone signal actually available to tissues, rather than the total hormone carried in the bloodstream. In short, it serves as a proxy for the body’s accessible thyroxine, offering a clearer picture of thyroid hormone activity at the cellular level.

When does correcting for TBG actually change the call?

The Free T4 Index (FTI, sometimes called T7) estimates the amount of free (unbound) thyroxine—the thyroid hormone that actually reaches cells. It is calculated from total T4 and a binding test to correct for changes in carrier proteins. Because free T4 drives metabolism in brain, heart, muscle, and gut, FTI clarifies thyroid effect.

Big picture: FTI links the pituitary–thyroid axis to liver-made binding proteins, so it is especially useful when those proteins shift (pregnancy, estrogen therapy, liver or kidney disease). Read with TSH and clinical context, it clarifies true thyroid status and helps anticipate cardiovascular, skeletal, metabolic, and cognitive consequences of chronic under- or over-thyroxine exposure.

How low, normal, and elevated FT4 Index values usually behave

FTI is a unitless index with lab-specific reference ranges; most euthyroid people sit near the middle. It is interpreted alongside TSH, and, in children and pregnancy, with age- and trimester-appropriate expectations.

When the index falls below range, tissues are seeing too little thyroxine. Primary hypothyroidism shows high TSH with low FTI; central (pituitary) causes show low/normal TSH with low FTI. People may feel tired, cold, constipated, and gain weight; skin and hair dry, heart rate slows, mood and thinking dull. Women can have heavy or irregular periods and fertility difficulty; in pregnancy, low maternal free T4 is linked to miscarriage and impaired fetal neurodevelopment. In children, growth and school performance can lag.

An index above range reflects thyrotoxicosis—excess hormone at the tissue level. Restlessness, heat intolerance, sweating, tremor, weight loss, diarrhea, and fast or irregular heartbeat can occur; older adults face atrial fibrillation and bone loss. Menstrual cycles may lighten or cease; in pregnancy, risks include hypertension and fetal growth issues. Children may show rapid growth and behavior changes.

Low values usually reflect too little available thyroid hormone (hypothyroxinemia), most often from primary thyroid failure (e.g., autoimmune hypothyroidism), less commonly from pituitary or hypothalamic disease (central hypothyroidism), or severe non‑thyroidal illness. System effects include slowed metabolism, fatigue, cold intolerance, weight gain, constipation, dry skin, bradycardia, mood and cognitive slowing, elevated LDL, and menstrual or fertility disturbances. In pregnancy, low values suggest inadequate maternal thyroid hormone for fetal neurodevelopment; older adults may present with subtler, cardiovascular‑leaning signs.

Being in range suggests steady thyroid hormone availability and a stable metabolic set point, supporting normal energy, heart rhythm, temperature, mood, cognition, lipid profile, and reproductive function. In ambulatory adults, values often cluster near the midrange when TSH is normal.

High values usually reflect excess available thyroid hormone (thyrotoxicosis) from Graves’ disease, toxic nodules, thyroiditis, or overtreatment. Common effects include heat intolerance, weight loss, tremor, anxiety, rapid or irregular heartbeat (including atrial fibrillation risk), bone loss, and menstrual irregularity. During pregnancy, high values can associate with maternal complications and fetal effects.

Binding proteins, assay quirks, and pregnancy-related shifts

Estrogen states (pregnancy, oral estrogens) raise TBG, while androgens, steroids, and nephrotic syndrome lower it; the index corrects for these. Critical illness, biotin, and heparin can distort immunoassays. Age‑ and trimester‑specific reference intervals apply. Many labs now favor direct free T4, but the Free T4 Index remains useful when binding proteins are abnormal. Interpretation is most appropriate alongside TSH and clinical context.

FT4 Index interpretation is most appropriate alongside TSH and clinical context. TSH localizes the lesion (primary vs central), and symptoms—plus pregnancy status, medications, and age—shape what the index means in practice for treatment dosing and follow-up timing.

FAQs

Free T4 Index (T7) is a calculated measure that combines Total T4 with a binding assessment (such as T3 uptake) to estimate unbound, biologically active thyroxine availability.

Testing Free T4 Index (T7) helps clarify thyroid status when binding proteins change, reduces misclassification versus Total T4 alone, and supports monitoring if you use levothyroxine.

Test periodically to establish a baseline and when circumstances that alter binding proteins occur (for example, pregnancy or starting/stopping estrogens or androgens). Trending can also be useful when adjusting thyroid hormone replacement.

TBG changes from pregnancy, oral estrogens, androgens, liver or kidney conditions, and genetic TBG variants can affect results. Severe illness, certain medications, assay interferences, and high-dose biotin supplements may also influence readings.

No fasting is typically required. Note current medications and supplements, and avoid high-dose biotin before the blood draw to reduce the risk of assay interference.

Superpower currently offers at-home blood testing in the following states: Alabama, Arizona, California, Colorado, Connecticut, Delaware, District of Columbia, Florida, Georgia, Idaho, Illinois, Indiana, Kansas, Maine, Maryland, Massachusetts, Michigan, Minnesota, Missouri, Montana, Nebraska, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Carolina, Ohio, Oklahoma, Oregon, Pennsylvania, South Carolina, Tennessee, Texas, Utah, Vermont, Virginia, Washington, West Virginia, and Wisconsin.

We’re actively expanding nationwide, with new states being added regularly. If your state isn’t listed yet, stay tuned.

References

  1. Schussler, G. C. (2000). The thyroxine-binding proteins. Thyroid, 10(2), 141-149. https://doi.org/10.1089/thy.2000.10.141
  2. Garber, J. R., Cobin, R. H., Gharib, H., Hennessey, J. V., Klein, I., Mechanick, J. I., Pessah-Pollack, R., Singer, P. A., & Woeber, K. A. (2012). Clinical practice guidelines for hypothyroidism in adults: Cosponsored by the American Association of Clinical Endocrinologists and the American Thyroid Association. Endocrine Practice, 18(6), 988-1028. https://doi.org/10.4158/EP12280.GL
  3. Jonklaas, J., Bianco, A. C., Bauer, A. J., Burman, K. D., Cappola, A. R., Celi, F. S., Cooper, D. S., Kim, B. W., Peeters, R. P., Rosenthal, M. S., & Sawka, A. M. (2014). Guidelines for the treatment of hypothyroidism: Prepared by the American Thyroid Association task force on thyroid hormone replacement. Thyroid, 24(12), 1670-1751. https://doi.org/10.1089/thy.2014.0028
  4. Sheehan, M. T. (2016). Biochemical testing of the thyroid: TSH is the best and, oftentimes, only test needed - A review for primary care. Clinical Medicine & Research, 14(2), 83-92. https://doi.org/10.3121/cmr.2016.1309
  5. Chaker, L., Bianco, A. C., Jonklaas, J., & Peeters, R. P. (2017). Hypothyroidism. The Lancet, 390(10101), 1550-1562. https://doi.org/10.1016/S0140-6736(17)30703-1

Built by the world’s top doctors and scientists

Dr Anant Vinjamoori, MD

Chief Longevity Officer, Superpower

Board-certified longevity physician. Previously product leader at Virta Health & CMO at Modern Age. Featured in  WSJ, Forbes, and Fortune.

Learn more

Dr Leigh Erin Connealy, MD

Clinician & Founder of The Centre for New Medicine

Leads the largest integrative medical clinic in North America. A pioneer in integrative oncology.

Learn more

Dr Robert Lufkin

UCLA Medical Professor, NYT Bestselling Author

A leading voice on metabolic health and longevity as shown in The Today Show, USA Today and FOX.

Learn more

Dr Abe Malkin

Founder & Medical Director of Concierge MD

Leads a nationwide medical practice, and Drip Hydration, a mobile IV therapeutics company

Learn more
Membership slide 1
Membership slide 1
Membership slide 2
Membership slide 3
1 / 3

Your membership starts here

Annual 100+ biomarker panel

Data dashboard and digital twin

Upload past labs and connect wearables

Personalized health protocol

24/7 care team access

AI companion for all health questions

Marketplace with additional solutions

$199

/year*

Billed annually

HSA/ FSA eligible
Cancel anytime
Results in a week

* Pricing may vary for members in New York and New Jersey